# Israel Biotech Fund

Israel Biotech Fund is a Private Equity based in Rehovot, Israel.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Rehovot, Israel
- **Region:** Middle East
- **Address:** Rehovot, Israel
- **Founded:** 2014
- **Assets under management:** Undisclosed
- **Website:** ibf.fund
- **LinkedIn:** https://www.linkedin.com/company/israel-biotech-fund

## Regulatory record

- **Reports private funds:** No

## About

Israel Biotech Fund is a Tel Aviv-based investment firm that focuses on clinical-stage biotechnology companies in Israel. It has made 14 investments, including a Series C investment in Ukko on January 1, 2025. The firm has also facilitated three portfolio exits, with the most recent being BioSight on July 27, 2023.

## Sectors

- Digital Health
- Healthcare Services

## Questions

### What investment stages does Israel Biotech Fund typically target?

The firm invests across the life-science development continuum, from preclinical seed rounds through to late-stage clinical assets and occasional crossover or PIPE transactions. By maintaining this flexible stage mandate, the fund can follow portfolio companies from academic spin-out through to regulatory approval and commercialization.

### How does Israel Biotech Fund source its deal flow?

The fund's deal pipeline is built on deep ties to Israeli academic tech-transfer offices, particularly those of the Weizmann Institute of Science and Hebrew University. Founding and senior team members with backgrounds at Teva and Israeli research institutions create a proprietary sourcing channel that surfaces therapeutic programs before they reach international syndicates.

### Which therapeutic areas does Israel Biotech Fund focus on?

The portfolio concentrates on precision oncology, immunology, and neurodegenerative diseases. Within these verticals, the fund backs both biologic and small-molecule drug-discovery platforms, as well as enabling technologies such as AI-driven target identification and novel drug-delivery systems.

### How does the firm interact with multinational pharmaceutical companies?

The fund frequently co-invests alongside or structures co-development agreements with global pharmaceutical partners. These relationships provide portfolio companies with validation, clinical development infrastructure, and eventual exit pathways, while giving pharma partners early access to Israeli-originated therapeutic innovation.

## Related profiles

- [I Squared Capital](https://altss.com/profile/i-squared-capital)
- [Israel-Colorado Innovation Fund](https://altss.com/profile/israel-colorado-innovation-fund)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/israel-biotech-fund

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology